Page last updated: 2024-12-06
terlakiren
Description
terlakiren: RN given for (R-(R*,S*))-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|
| PubMed CID | 64922 |
| CHEMBL ID | 60550 |
| CHEBI ID | 177676 |
| SCHEMBL ID | 123300 |
| MeSH ID | M0206851 |
Synonyms (30)
| Synonym |
|---|
| propan-2-yl (2r,3s)-4-cyclohexyl-2-hydroxy-3-[[(2r)-3-methylsulanyl-2-[[(2s)-2-(morpholine-4-carbonylamino)-3-phenylpropanoyl]amino]propanoyl]amino]butanoate |
| CHEBI:177676 |
| D03743 |
| terlakiren (usan/inn) |
| 119625-78-4 |
| terlakiren |
| CHEMBL60550 , |
| cp-80,794 |
| cp-80794 |
| propan-2-yl (2r,3s)-4-cyclohexyl-2-hydroxy-3-[[(2r)-3-methylsulfanyl-2-[[(2s)-2-(morpholine-4-carbonylamino)-3-phenylpropanoyl]amino]propanoyl]amino]butanoate |
| (2s,4r)-4-cyclohexyl-2-hydroxy-3-((r)-3-methylsulfanyl-2-{2-[(morpholine-4-carbonyl)-amino]-3-phenyl-propionylamino}-propionylamino)-butyric acid isopropyl ester |
| bdbm50282993 |
| l-cysteinamide, n-(4-morpholinylcarbonyl)-l-phenylalanyl-n-(1-(cyclohexylmethyl)-2-hydroxy-3-(1-methylethoxy)-3-oxopropyl)-s-methyl-, (r-(r*,s*))- |
| e5h9ip637w , |
| unii-e5h9ip637w |
| terlakiren [usan:inn] |
| isopropyl (alphar,betas)-alpha-hydroxy-beta-((r)-3-(methylthio)-2-((s)-alpha-4-morpholinecarboxamidohydrocinnamamido)propionamido)cyclohexanebutyrate |
| cp 80794 |
| n-(morpholin-4-ylcarbonyl)-l-phenylalanyl-n-[(1r,2s)-1-(cyclohexylmethyl)-2-hydroxy-3-(1-methylethoxy)-3-oxopropyl]-s-methyl-l-cysteinamide |
| 2zs , |
| SCHEMBL123300 |
| terlakiren [inn] |
| terlakiren [usan] |
| DTXSID00152533 |
| isopropyl (2r,3s)-4-cyclohexyl-2-hydroxy-3-{[(2r)-3-(methylsulfanyl)-2-({(2s)-2-[(4-morpholinylcarbonyl)amino]-3-phenylpropanoyl}amino)propanoyl]amino}butanoate |
| n-(morpholin-4-ylcarbonyl)-l-phenylalanyl-n-[(1s,2r)-1-(cyclohexylmethyl)-2-hydroxy-3-(1-methylethoxy)-3-oxopropyl]-s-methyl-l-cysteinamide |
| Q27276899 |
| HY-105205 |
| CS-0025355 |
| AKOS040749633 |
Research Excerpts
Dosage Studied
| Excerpt | Relevance | Reference |
|---|
| " Dose-response curves for CP-80,794 (0." | ( Synergistic effect on reduction in blood pressure with coadministration of the renin inhibitor, CP-80,794, and the angiotensin converting enzyme inhibitor, captopril.
Barber, RL; Fossa, AA; Murphy, WR; Nocerini, MR; Rauch, AL; Swindell, AC; Weinberg, LJ, 1992) | 0.28 |
Drug Classes (1)
| Class | Description |
|---|
| peptide | Amide derived from two or more amino carboxylic acid molecules (the same or different) by formation of a covalent bond from the carbonyl carbon of one to the nitrogen atom of another with formal loss of water. The term is usually applied to structures formed from alpha-amino acids, but it includes those derived from any amino carboxylic acid. X = OH, OR, NH2, NHR, etc. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein Targets (1)
Inhibition Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|
| Cathepsin D | Bos taurus (cattle) | IC50 (µMol) | 0.0240 | 0.0070 | 0.9165 | 6.3000 | AID47841 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Ceullar Components (3)
Bioassays (3)
| Assay ID | Title | Year | Journal | Article |
|---|
| AID125833 | Maximum fall in mean arterial blood pressure expressed in mmHg following a 30 mg/kg dose in monkeys. | 1991 | Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
| Renin inhibitors containing esters at the P2-position. Oral activity in a derivative of methyl aminomalonate. |
| AID47841 | Inhibitory concentration on Bovine Cathepsin D | 1991 | Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
| Renin inhibitors containing esters at the P2-position. Oral activity in a derivative of methyl aminomalonate. |
| AID195613 | Inhibition of monkey plasma renin | 1991 | Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
| Renin inhibitors containing esters at the P2-position. Oral activity in a derivative of methyl aminomalonate. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (6)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.50
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| Metric | This Compound (vs All) |
|---|
| Research Demand Index | 12.50 (24.57) | | Research Supply Index | 1.95 (2.92) | | Research Growth Index | 4.45 (4.65) | | Search Engine Demand Index | 0.00 (26.88) | | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |